Measles Control Campaign Update

During the three month period of the Campaign, the uptake of measles-mumps-rubella (MMR) vaccine given at primary school clinics and the number of adverse events following MMR vaccination are being monitored. Data are forwarded to the National Centre for Disease Control for collation and will be a major element in the evaluation of the Campaign.

School immunisation teams collect data on the following variables:
- total enrolments per year/grade for each primary school;
- total number of consent forms returned per year/grade;
- total number of consents given for vaccination at school; and
- total number of children vaccinated at school clinics.

Communicable Diseases Intelligence will routinely report on the progress of the proportion of children enrolled in primary schools by State/ Territory who:
- return consent forms;
- consent to be vaccinated; and
- are vaccinated at school during the Campaign.

It should be noted that the lag period from the time of vaccination to central data entry varies between States and Territories. Further, figures do not include all children who are vaccinated at venues and times alternate to the scheduled school based clinics. These data will however be collected as part of the overall evaluation of the Campaign.

Any serious adverse events after vaccination occurring during the Campaign are being assessed by a panel of experts who meet once a week.

Measles Control Campaign activity data, to 26 August 1998

- Sum total students: 248,714
- Total forms returned: 232,335
- Consents to vaccinate: 195,729
- Total students immunised: 183,788

Percentages are as follows:
- Of total students: 93% returned their forms
- Of total forms returned: 84% consent to vaccination
- Of total consents to vaccination: 94% have been vaccinated
- Of total students: 74% vaccinated.

Adverse events
- Anaphylaxis: 3
- Syncopal fits: 2
- Faints: 2
- Hyperventilation: 1
- Local reactions: 2
- Arthritis with fever: 1

Enquiries can be directed to Sue Campbell-Lloyd, National Manager of the Measles Control Campaign, Sydney Office, Commonwealth Department of Health and Family Services.

Typhoid vaccine

CSL have advised that they have ceased production of their whole-cell typhoid vaccine, which will no longer be available once present stocks run out. The product has been replaced by the purified capsular polysaccharide vaccine Typhim Vi, made by Pasteur Merieux. This vaccine is equally effective and produces fewer adverse reactions. The CSL oral live-attenuated typhoid vaccine, Typh-Vax (Oral) will remain available for those who prefer not to have injections.

As Typhim Vi is not presently approved for use in Australia in children under the age of 5 years, CSL have maintained a stock of long-dated doses of the whole-cell vaccine for use in children.